ATE321063T1 - Neue immunoeffectorverbindungen - Google Patents
Neue immunoeffectorverbindungenInfo
- Publication number
- ATE321063T1 ATE321063T1 AT01959445T AT01959445T ATE321063T1 AT E321063 T1 ATE321063 T1 AT E321063T1 AT 01959445 T AT01959445 T AT 01959445T AT 01959445 T AT01959445 T AT 01959445T AT E321063 T1 ATE321063 T1 AT E321063T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- new
- antigen
- present
- immunoeffector
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- SXSXOQFGUZXAEK-SXTMZTKSSA-N N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O.N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O.N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O SXSXOQFGUZXAEK-SXTMZTKSSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical group N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22305600P | 2000-08-04 | 2000-08-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE321063T1 true ATE321063T1 (de) | 2006-04-15 |
Family
ID=22834828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01959445T ATE321063T1 (de) | 2000-08-04 | 2001-08-03 | Neue immunoeffectorverbindungen |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7129219B2 (https=) |
| EP (1) | EP1311522B1 (https=) |
| JP (1) | JP4843181B2 (https=) |
| AT (1) | ATE321063T1 (https=) |
| AU (2) | AU2001281001B2 (https=) |
| CA (1) | CA2417806C (https=) |
| DE (1) | DE60118207T2 (https=) |
| ES (1) | ES2261453T3 (https=) |
| WO (1) | WO2002012258A1 (https=) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002255513B2 (en) | 2002-02-04 | 2008-03-06 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
| DE60234386D1 (de) * | 2002-02-04 | 2009-12-24 | Corixa Corp | Neue immuneffektor-verbindungen |
| US6525028B1 (en) | 2002-02-04 | 2003-02-25 | Corixa Corporation | Immunoeffector compounds |
| US6911434B2 (en) * | 2002-02-04 | 2005-06-28 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
| US7288640B2 (en) | 2002-07-08 | 2007-10-30 | Corixa Corporation | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor |
| ES2456066T3 (es) * | 2002-07-08 | 2014-04-21 | Corixa Corporation | Procesos para la producción de fosfato de aminoalquil glucosaminida e inmunoefectores disacáridos, e intermedios para ello |
| CN101863930A (zh) | 2003-01-06 | 2010-10-20 | 科里克萨有限公司 | 一些氨烷基氨基葡糖苷磷酸酯化合物和它们的用途 |
| US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
| US7998930B2 (en) * | 2004-11-04 | 2011-08-16 | Hanall Biopharma Co., Ltd. | Modified growth hormones |
| KR101515078B1 (ko) | 2005-12-22 | 2015-04-24 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
| GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
| CA2690708A1 (en) | 2007-06-26 | 2008-12-31 | Glaxosmithkline Biologicals S.A. | Vaccine |
| AU2011230619C1 (en) | 2010-03-25 | 2016-06-23 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
| GB201009273D0 (en) * | 2010-06-03 | 2010-07-21 | Glaxosmithkline Biolog Sa | Novel vaccine |
| GB201101331D0 (en) * | 2011-01-26 | 2011-03-09 | Glaxosmithkline Biolog Sa | Compositions and uses |
| HUE037408T2 (hu) | 2011-06-10 | 2018-08-28 | Univ Oregon Health & Science | CMV glikoproteinek és rekombináns vektorok |
| GB201113570D0 (en) | 2011-08-05 | 2011-09-21 | Glaxosmithkline Biolog Sa | Vaccine |
| CA2789539A1 (en) | 2011-09-12 | 2013-03-12 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
| ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
| DE102012222886B4 (de) * | 2012-12-12 | 2014-11-27 | Jöst Gmbh | Genopptes Schleif- und Reinigungsvlies sowie Herstellung und Verwendung desselben |
| CN105188710A (zh) | 2013-03-15 | 2015-12-23 | 葛兰素史密丝克莱恩生物有限公司 | 包含缓冲的氨基烷基氨基葡糖苷磷酸酯衍生物的组合物及其用于增强免疫应答的用途 |
| EP2848937A1 (en) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Methods of identifying novel HIV-1 immunogens |
| US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| EP3116479A1 (en) | 2014-03-12 | 2017-01-18 | GlaxoSmithKline Biologicals S.A. | Liposomal compositions for mucosal delivery |
| BE1022518B1 (fr) | 2014-03-12 | 2016-05-19 | Glaxosmithkline Biologicals S.A. | Formulation liposomale immunogene |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| EP3069730A3 (en) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
| US9931394B2 (en) | 2015-03-23 | 2018-04-03 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| TW201716084A (zh) | 2015-08-06 | 2017-05-16 | 葛蘭素史克智慧財產發展有限公司 | 組合物及其用途與治療 |
| WO2017021912A1 (en) | 2015-08-06 | 2017-02-09 | Glaxosmithkline Intellectual Property Development Limited | Combined tlrs modulators with anti ox40 antibodies |
| EP3331565A1 (en) | 2015-08-06 | 2018-06-13 | GlaxoSmithKline Intellectual Property Development Ltd | Tlr4 agonists and compositions thereof and their use in the treatment of cancer |
| CN107849084B (zh) | 2015-12-03 | 2021-09-14 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为sting调节剂的环状嘌呤二核苷酸 |
| WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
| WO2017112797A1 (en) * | 2015-12-22 | 2017-06-29 | Thomas Jefferson University | Intra-lesional cmv-based cancer vaccines |
| WO2017153952A1 (en) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
| JP2019510802A (ja) | 2016-04-07 | 2019-04-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | タンパク質調節物質として有用な複素環アミド |
| PT3440076T (pt) | 2016-04-07 | 2022-07-29 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas úteis como modeladores de proteína |
| KR20190003699A (ko) | 2016-05-05 | 2019-01-09 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 제스트 인핸서 상동체 2 억제제 |
| US20190241573A1 (en) | 2016-07-20 | 2019-08-08 | Glaxosmithkline Intellectual Property Development Limited | Isoquinoline derivatives as perk inhibitors |
| WO2018100536A1 (en) | 2016-12-01 | 2018-06-07 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating cancer |
| US11389465B2 (en) | 2017-05-01 | 2022-07-19 | Vanderbilt University | Phosphorylated hexaacyl disaccharides (PHADs) for treating or preventing infections |
| WO2019021208A1 (en) | 2017-07-27 | 2019-01-31 | Glaxosmithkline Intellectual Property Development Limited | USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS |
| WO2019053617A1 (en) | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | CHEMICAL COMPOUNDS |
| AU2018344902B2 (en) | 2017-10-05 | 2021-06-03 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (STING) useful in treating HIV |
| CA3077337A1 (en) | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (sting) |
| JP7362667B2 (ja) | 2018-02-12 | 2023-10-17 | イニミューン・コーポレーション | Ｔｏｌｌ様受容体リガンド |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| WO2020030571A1 (en) | 2018-08-06 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Combinations of a pd-1 antibody and a tlr4 modulator and uses thereof |
| WO2020030570A1 (en) | 2018-08-06 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Combinations of an ox40 antibody and a tlr4 modulator and uses thereof |
| WO2020031087A1 (en) | 2018-08-06 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
| EP3886901A1 (en) | 2018-11-29 | 2021-10-06 | GlaxoSmithKline Biologicals S.A. | Methods for manufacturing an adjuvant |
| US20220227761A1 (en) | 2019-05-16 | 2022-07-21 | Stingthera, Inc. | Oxoacridinyl acetic acid derivatives and methods of use |
| WO2020232378A1 (en) | 2019-05-16 | 2020-11-19 | Silicon Swat, Inc. | Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use |
| EP3990494A1 (en) | 2019-06-26 | 2022-05-04 | GlaxoSmithKline Intellectual Property Development Limited | Il1rap binding proteins |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| US20220273789A1 (en) | 2019-07-21 | 2022-09-01 | Glaxosmithkline Biologicals Sa | Therapeutic viral vaccine |
| WO2021018941A1 (en) | 2019-07-31 | 2021-02-04 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating cancer |
| WO2021043961A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy |
| WO2021048081A1 (en) | 2019-09-09 | 2021-03-18 | Glaxosmithkline Biologicals Sa | Immunotherapeutic compositions |
| WO2021058711A2 (en) | 2019-09-27 | 2021-04-01 | Glaxosmithkline Intellectual Property Development Limited | Antigen binding proteins |
| EP4077318B1 (en) | 2019-12-18 | 2025-10-15 | Ctxt Pty Ltd | Benzimidazole dimers as modulators of sting |
| WO2021245611A1 (en) | 2020-06-05 | 2021-12-09 | Glaxosmithkline Biologicals Sa | Modified betacoronavirus spike proteins |
| EP4032547A1 (en) | 2021-01-20 | 2022-07-27 | GlaxoSmithKline Biologicals S.A. | Hsv1 fce derived fragements for the treatment of hsv |
| CA3212345A1 (en) | 2021-03-02 | 2022-09-09 | Glaxosmithkline Intellectual Property Development Limited | Substituted pyridines as dnmt1 inhibitors |
| JP2024511831A (ja) | 2021-03-31 | 2024-03-15 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 抗原結合タンパク質およびそれらの組み合わせ |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6113918A (en) * | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| US6013640A (en) * | 1998-08-21 | 2000-01-11 | Ribi Immunochem Research, Inc. | Phosphoglycolipid and methods for its use |
| US6911434B2 (en) * | 2002-02-04 | 2005-06-28 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
| US6525028B1 (en) * | 2002-02-04 | 2003-02-25 | Corixa Corporation | Immunoeffector compounds |
-
2001
- 2001-08-03 CA CA2417806A patent/CA2417806C/en not_active Expired - Lifetime
- 2001-08-03 ES ES01959445T patent/ES2261453T3/es not_active Expired - Lifetime
- 2001-08-03 AU AU2001281001A patent/AU2001281001B2/en not_active Expired
- 2001-08-03 EP EP01959445A patent/EP1311522B1/en not_active Expired - Lifetime
- 2001-08-03 AU AU8100101A patent/AU8100101A/xx active Pending
- 2001-08-03 JP JP2002518232A patent/JP4843181B2/ja not_active Expired - Lifetime
- 2001-08-03 AT AT01959445T patent/ATE321063T1/de not_active IP Right Cessation
- 2001-08-03 WO PCT/US2001/024284 patent/WO2002012258A1/en not_active Ceased
- 2001-08-03 DE DE60118207T patent/DE60118207T2/de not_active Expired - Lifetime
- 2001-08-03 US US10/469,620 patent/US7129219B2/en not_active Expired - Lifetime
-
2006
- 2006-09-11 US US11/519,275 patent/US7501399B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US20070004914A1 (en) | 2007-01-04 |
| CA2417806A1 (en) | 2002-02-14 |
| EP1311522A4 (en) | 2004-06-09 |
| WO2002012258A1 (en) | 2002-02-14 |
| CA2417806C (en) | 2011-05-10 |
| JP4843181B2 (ja) | 2011-12-21 |
| ES2261453T3 (es) | 2006-11-16 |
| AU2001281001B2 (en) | 2005-11-03 |
| DE60118207T2 (de) | 2006-11-09 |
| DE60118207D1 (de) | 2006-05-11 |
| AU8100101A (en) | 2002-02-18 |
| US20040132988A1 (en) | 2004-07-08 |
| US7501399B2 (en) | 2009-03-10 |
| EP1311522B1 (en) | 2006-03-22 |
| EP1311522A1 (en) | 2003-05-21 |
| US7129219B2 (en) | 2006-10-31 |
| JP2004505986A (ja) | 2004-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE321063T1 (de) | Neue immunoeffectorverbindungen | |
| CY1109692T1 (el) | Νεες ανοσοδραστικες συνθεσεις | |
| TR200103018T2 (tr) | İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri. | |
| CY1118443T1 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
| EA021242B9 (ru) | Антитела к остеопротегерин лиганду (опгл) | |
| ATA155598A (de) | Neue influenzavirus-impfstoffzusammensetzung | |
| CY1107628T1 (el) | Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων | |
| EA200300464A1 (ru) | ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ | |
| ATE382690T1 (de) | Modulierung der durch cpg-oligonukleotide verursachte immunstimulierung durch positionsbedingte veränderung von nukleosiden | |
| CY1112993T1 (el) | Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1 | |
| DE602004029904D1 (de) | Neue tricyclische nukleoside oder nukleotide als therapeutische mittel | |
| MXPA05014016A (es) | Proteinas portadoras para vacunas. | |
| TW200633719A (en) | Glycoconjugate vaccines containing peptidoglycan | |
| DE60121545D1 (de) | Virus des porzinen reproduktiven und respiratorischen syndroms und dessen verwendung | |
| BR9913446A (pt) | Produtos de aglicona e métodos de uso | |
| AU1922902A (en) | Novel means for the diagnosis and therapy of CTCL | |
| FI20011664A7 (fi) | Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö | |
| FI20011671A7 (fi) | Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö | |
| ES2196150T3 (es) | Induccion de tolerancia inmunologica por el uso de anticuerpos anti-cd4 que no inducen deplecion. | |
| BR0015872A (pt) | Agentes antitrombóticos | |
| YU68602A (sh) | Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje | |
| NO20022969D0 (no) | Sammensetninger og metoder for L-nukleosider, L-nukleotider og analoger derav | |
| DK0858465T3 (da) | Protein med antitumorvirkning. | |
| UA11507U (uk) | Спосіб лікування гострих кишкових інфекцій у дітей | |
| BR1100558A (pt) | famìlia de anticorpos modificados, com elevada afinidade, para tratamento de cáncer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |